CanSino Biologics (Germany) Performance
| CJH Stock | EUR 3.32 0.06 1.84% |
On a scale of 0 to 100, CanSino Biologics holds a performance score of 12. The firm shows a Beta (market volatility) of 0.54, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CanSino Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding CanSino Biologics is expected to be smaller as well. Please check CanSino Biologics' standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether CanSino Biologics' price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in CanSino Biologics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, CanSino Biologics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 4.4 B | |
| Total Cashflows From Investing Activities | -2.6 B |
CanSino |
CanSino Biologics Relative Risk vs. Return Landscape
If you would invest 202.00 in CanSino Biologics on September 2, 2024 and sell it today you would earn a total of 130.00 from holding CanSino Biologics or generate 64.36% return on investment over 90 days. CanSino Biologics is currently producing 0.9338% returns and takes up 6.032% volatility of returns over 90 trading days. Put another way, 53% of traded stocks are less volatile than CanSino, and 82% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CanSino Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CanSino Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CanSino Biologics, and traders can use it to determine the average amount a CanSino Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1548
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CJH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.03 actual daily | 53 53% of assets are less volatile |
Expected Return
| 0.93 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average CanSino Biologics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CanSino Biologics by adding it to a well-diversified portfolio.
CanSino Biologics Fundamentals Growth
CanSino Stock prices reflect investors' perceptions of the future prospects and financial health of CanSino Biologics, and CanSino Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CanSino Stock performance.
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Current Valuation | 3.4 B | |||
| Shares Outstanding | 114.78 M | |||
| Price To Book | 2.36 X | |||
| Price To Sales | 2.21 X | |||
| Revenue | 4.3 B | |||
| EBITDA | 2.05 B | |||
| Cash And Equivalents | 6.71 B | |||
| Cash Per Share | 27.12 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.13 % | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.55 X | |||
| Total Asset | 11.87 B | |||
About CanSino Biologics Performance
By analyzing CanSino Biologics' fundamental ratios, stakeholders can gain valuable insights into CanSino Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CanSino Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CanSino Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the Peoples Republic of China. CANSINO BIOLOGICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 726 people.Things to note about CanSino Biologics performance evaluation
Checking the ongoing alerts about CanSino Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CanSino Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CanSino Biologics is way too risky over 90 days horizon | |
| CanSino Biologics appears to be risky and price may revert if volatility continues | |
| About 27.0% of the company shares are held by company insiders |
- Analyzing CanSino Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CanSino Biologics' stock is overvalued or undervalued compared to its peers.
- Examining CanSino Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CanSino Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CanSino Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CanSino Biologics' stock. These opinions can provide insight into CanSino Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CanSino Stock analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Transaction History View history of all your transactions and understand their impact on performance |